ATS 2022
TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Your search for oral corticosteroids returned 2 results
ATS Virtual Program 2020
Low-Severity COPD: Risk for Exacerbation, Hospitalization, and Death
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
